Deep Genomics CEO Brian O'Callaghan honored as gold stevie(r) Award winner in 2025 Stevie Awards for Technology Excellence. August 1, 2026 TORONTO, August 1, 2025 - Brian O'Callaghan, CEO of Deep Genomics, the AI-first TechBio organization pioneering a new path for genomic R&D, has been named Biotech Executive of the Year, winning gold in the second annual Stevie Awards for Technology Excellence. Since his appointment as CEO in September 2023, O'Callaghan has led Deep Genomics into a new era of innovation and growth, helping to transition the company from a single-model initiative to a fully integrated platform of AI foundation models for drug discovery. Deep Genomics has been a pioneer in the drug discovery space through its cohesive AI foundation model platform, which dramatically accelerates therapeutic discovery. The company's flagship AI foundation model, BigRNA, is reshaping the landscape of RNA research and development with 1.8 billion tunable parameters trained on over one trillion genomic signals. Under O'Callaghan's leadership, Deep Genomics launched additional proprietary AI foundation models that work alongside BigRNA, including DeepADAR for RNA editing and REPRESS, which accurately predicts microRNA (miRNA) binding and mRNA degradation directly from RNA sequences. O'Callaghan has also driven the strategic and structural expansion of Deep Genomics, opening a new lab and office in Cambridge, Massachusetts, expanding its Toronto headquarters, and appointing key leaders across science and business functions. "Winning a Stevie Award is a reflection of the extraordinary talent and mission-driven mindset at Deep Genomics," said O'Callaghan. "Our AI foundation model platform is unlocking AI-driven drug discovery in a way that was previously inconceivable, and I'm incredibly proud of our team for driving innovations that bring us closer to transforming care for patients." "We're proud to honor the 2025 Stevie Awards for Technology Excellence winners for their remarkable achievements," said Stevie Awards President Maggie Miller. "We look forward to celebrating their innovation and impact at the awards ceremony on September 16." The Stevie Awards for Technology Excellence recognize the remarkable achievements of individuals, teams, and organizations that are shaping the future of technology across all industry sectors. Winners of the awards, named the Stevies from the Greek word meaning "crowned," will be recognized during a gala awards event on Tuesday, September 16, at the Marriott Marquis Hotel in New York City. More than 160 professionals worldwide participated in the judging process to select this year's honorees. Details about the Stevie Awards for Technology Excellence and the list of 2025 Stevie winners are available at www.StevieAwards.com/Tech. About Deep Genomics Deep Genomics is an AI-first TechBio organization pioneering a new path for genomic R&D through its multidisciplinary team of AI and biology scientists and its Foundation Model Platform. Leveraging cutting-edge AI technologies and biological insights, Deep Genomics is at the forefront of revolutionizing drug discovery and development. Through its innovative approach and collaborative partnerships, Deep Genomics aims to accelerate the delivery of life-saving therapeutics to patients worldwide. Deep Genomics is located in Toronto, Ontario, and Cambridge, Massachusetts. For more information, visit www.deepgenomics.com and follow Deep Genomics on LinkedIn. About the Stevie Awards Stevie Awards are conferred in nine programs: the Asia-Pacific Stevie Awards, the German Stevie Awards, the Middle East & North Africa Stevie Awards, The American Business Awards(R), The International Business Awards(R), the Stevie Awards for Great Employers, the Stevie Awards for Women in Business, the Stevie Awards for Technology Excellence and the Stevie Awards for Sales & Customer Service. Stevie Awards competitions receive more than 12,000 entries each year from organizations in more than 70 nations and territories. Honoring organizations of all types and sizes and the people behind them, the Stevies recognize outstanding performance in the workplace worldwide. Learn more about the Stevie Awards at http://www.StevieAwards.com. Media Contact: [email protected]

Deep Genomics appoints Thong Q. Le as Chair of the Board of Directors. July 23, 2026 CAMBRIDGE, Mass. & TORONTO - Deep Genomics, the AI-first TechBio organization pioneering a new path for genomic medicines with its AI foundation model platform, today announced the appointment of Thong Q. Le as chair of its Board of Directors. "Since joining our Board in 2025, Thong has been a trusted advisor and a strong advocate for our vision," said Brendan Frey, Founder and Chief Innovation Officer of Deep Genomics. "He brings a fresh energy and deep experience supporting the life sciences industry to the role, making him exceptionally well positioned to lead our Board as Deep Genomics continues to advance AI-driven drug discovery." Mr. Le joined the Deep Genomics Board of Directors in 2025, bringing more than 20 years of experience investing in the life sciences sector. Throughout his career, he has guided high-impact investments and supported deal-making efforts that have driven meaningful health outcomes. He also serves as investment director and managing partner of the Strategic Investment Fund (SIF) for the Gates Foundation, and chairman of Accelerator Life Science Partners (ALSP), a venture capital firm dedicated to building next-generation life science companies. As Chair, Mr. Le will help guide Deep Genomics through its next phase of growth as the company advances its internal pipeline toward clinical development, expands strategic collaborations, and further establishes its leadership at the intersection of AI, genomics, and drug discovery. "I'm honored to take on the role of Chair of the Board of Directors at such an exciting time for Deep Genomics and the broader TechBio industry," said Le. "Deep Genomics has built a unique platform and world-class team leading at the intersection of AI and biology. I look forward to continuing my work alongside the company as it advances its mission to transform how medicines are discovered and developed." Mr. Le succeeds Chip Baird, who served as Chair of the Board for the past three years. Mr. Baird will continue to support Deep Genomics as a non-executive director and will serve as Chair of the Audit Committee. To learn more about Deep Genomics' work and its groundbreaking impact in the realm of genomic R&D, visit www.deepgenomics.com. For those interested in joining this team of TechBio innovators, visit https://www.deepgenomics.com/careers/. About Deep Genomics Deep Genomics is a fully integrated AI-first TechBio company pioneering a new approach to drug discovery with its Biological Foundation Model (BioFM) platform. At the intersection of genomics, drug development, and AI, Deep Genomics brings together a world-class team of scientists, engineers, and researchers to solve complex biological challenges at scale and accelerate the discovery and development of genetic medicines to improve patient outcomes. Deep Genomics is located in Toronto, Ontario, and Cambridge, Massachusetts. For more information, visit www.deepgenomics.com and follow Deep Genomics Inc. on LinkedIn and Twitter.